A Postmarketing Pharmacovigilance Study of Fenfluramine: Adverse Event Data Mining and Analysis Based on the US Food and Drug Administration Public Data Open Project (openFDA)

被引:0
|
作者
Chen, Tianyu [1 ]
Chen, Qiying [2 ]
Zhang, Yuezhen [1 ]
Liu, Ting [1 ,2 ]
机构
[1] Quanzhou Med Coll, 950 Donghai St, Quanzhou 362000, Fujian, Peoples R China
[2] Fujian Med Univ, Affiliated Hosp 2, 950 Donghai St, Quanzhou 362000, Fujian, Peoples R China
关键词
Fenfluramine; openFDA; Adverse events; Pharmacovigilance; DRAVET;
D O I
10.1016/j.pediatrneurol.2025.03.001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: A postmarketing analysis of the adverse events (AEs) associated with fenfluramine (FFA) was conducted using the US Food and Drug Administration's Open Public Data Program (openFDA). Methods: The openFDA database was queried to retrieve FFA AE reports. Two algorithms, namely, the reporting odds ratio (ROR) and proportional reporting ratio, were employed for the purpose of detecting potential safety signals. Results: From the openFDA data platform, a total of 6,269,521 AE reports were collected during the study period; the number of AE reports with FFA as the primary suspect was 2386. Of these, 1526 (63.96%) were reported by consumers or non-health professionals, 2009 (84.20%) were reported by the United States, 1053 (44.13%) were unknown indications, and serious AEs were reported in 1315 cases (55.11%). A total of 62 signals were generated. The top 10 signals included atonic seizures (ROR of 918.52, 95% confidence interval [CI]: 670.65-1257.99), seizure clusters (ROR of 787.02, 95% CI: 595.26-1040.56), mitral valve thickening (ROR of 773.94, 95% CI: 463.47-1292.38), pulmonary valve incompetence (ROR of 600.71, 95% CI: 432.09-835.13), echocardiogram abnormal (ROR of 417.13, 95% CI: 307.87-565.16), change in seizure presentation (ROR of 287.55, 95% CI: 214.81-384.91), tricuspid valve incompetence (ROR of 221.42, 95% CI: 179.68-272.84), aortic valve incompetence (ROR of 176.59, 95% CI: 131.89-236.45), tonic convulsion (ROR of 173.68, 95% CI: 110.28-273.54), and myoclonic epilepsy (ROR of 158.05, 95% CI: 102.60-243.46). Conclusions: This study employed the openFDA database to identify safety signals associated with FFA, thereby offering significant insights for clinical monitoring and risk identification in patients undergoing FFA therapy. (c) 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:96 / 102
页数:7
相关论文
共 50 条
  • [31] An Ecological Study on Consumer Adverse Event Reporting to the US Food and Drug Administration
    Munoz, M.
    Dal Pan, G.
    Xiao, H.
    Delcher, C.
    Wei, J.
    Kortepeter, C.
    Winterstein, A.
    DRUG SAFETY, 2018, 41 (11) : 1132 - 1132
  • [32] A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system
    Shu, Yamin
    Ding, Yufeng
    Dai, Bing
    Zhang, Qilin
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (04) : 563 - 572
  • [33] Malignancies and ustekinumab: an analysis of the US Food and Drug Administration Adverse Event Reporting System and the European Union Drug Regulating Authorities Pharmacovigilance database
    Florek, A. G.
    Nardone, B.
    Thareja, S.
    Tran, G.
    Giles, F. J.
    West, D. P.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) : E220 - E221
  • [34] Disproportionality Analysis of Lenvatinib-Caused Gastrointestinal Perforation in Cancer Patients: A Pharmacovigilance Analysis Based on the US Food and Drug Administration Adverse Event Reporting System
    Zhou, Jianxing
    Wei, Zipeng
    Zheng, You
    Xie, Helin
    Cao, Wanxia
    Cai, Xinying
    Huang, Jialin
    Wu, Xuemei
    JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (10): : 1133 - 1140
  • [35] Association of Antipsychotic Drugs with Venous Thromboembolism: Data Mining of Food and Drug Administration Adverse Event Reporting System and Mendelian Randomization Analysis
    Li, Tong
    Hu, Kai
    Ye, Ling
    Ma, Junlong
    Huang, Longjian
    Guo, Chengjun
    Huang, Xin
    Jiang, Jie
    Xie, Xiaoxue
    Guo, Chengxian
    He, Qingnan
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2024, 31 (04) : 396 - 418
  • [36] Post-Marketing Safety of Temozolomide: A Pharmacovigilance Study Based on the Food and Drug Administration Adverse Event Reporting System
    Lin, Yuhao
    Deng, Muling
    Xu, Siqi
    Chen, Chuanben
    Ding, Jianming
    ONCOLOGY, 2025,
  • [37] Detection and analysis of signals of adverse events of memantine based on the US food and drug administration adverse event reporting system
    Zhang, Weichui
    Chen, Mianhai
    Cai, Xiaolin
    Zhang, Mengting
    Hu, Mianda
    Hu, Yanghui
    Yang, Yurong
    Zhu, Jinfeng
    Du, Yikuan
    Yang, Chun
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (05) : 617 - 625
  • [38] Electronic reporting of adverse event data to the Food and Drug Administration: The experiences of Glaxo Wellcome and Zeneca as participants in the Adverse Event Reporting System pilot project
    Blake, M
    Pinkston, V
    DRUG INFORMATION JOURNAL, 1999, 33 (04): : 1101 - 1108
  • [39] Electronic Reporting of Adverse Event Data to the Food and Drug Administration: The Experiences of Glaxo Wellcome And Zeneca As Participants in the Adverse Event Reporting System Pilot Project
    Mark Blake
    Vlasta Pinkston
    Drug information journal : DIJ / Drug Information Association, 1999, 33 (4): : 1101 - 1108
  • [40] Safety signals of albumin-bound paclitaxel: Data mining of the Food and Drug Administration adverse event reporting system
    Wang, Yuwei
    Liu, Xiao
    INDIAN JOURNAL OF PHARMACOLOGY, 2023, 55 (03) : 167 - 173